Year in review
- 1 March 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 31 (2) , 139-147
Abstract
Transcatheter aortic valve replacement (TAVR) has been effective in prohibitive/high-risk patients. Expansion toward intermediate or even low-risk patients has been proposed. A review of recent developments will help understand current trends and issues. The 5-year results from the PARTNER I trial and 2-year results of the CoreValve US Pivotal Trial, together with national registries, confirmed the long-term efficacy and durability of TAVR. Studies including PARTNER II, ADVANCE, and The German Aortic Valve Registry showed short-to mid-term success in intermediate-risk patients. Comparison of balloon-expandable and self-expanding valves in the CHOICE trial associated specific outcome differences with specific valve types, suggesting a more customized approach in valve selection. Short-term results of newer-generation valves have demonstrated excellent safety and efficacy with improved designs. Studies on TAVR-specific complications, such as conduction block and arrhythmia, paravalvular aortic regurgitation, and stroke, have renewed ideas about their prognosis, treatment, and prevention. Conscious sedation percutaneous TAVR has become more popular, with excellent outcomes and improved cost savings. TAVR has been accepted as an effective treatment even for intermediate-risk patients. This article aims to review the most recent results and essential issues.Keywords
This publication has 36 references indexed in Scilit:
- 2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Deemed Extreme Risk for SurgeryJACC, 2015
- 1-Year Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable ValvesJACC, 2015
- 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve ReplacementJACC, 2015
- 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trialThe Lancet, 2015
- 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trialThe Lancet, 2015
- Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve StenosisJACC, 2015
- European Experience With the Second-Generation Edwards SAPIEN XT Transcatheter Heart Valve in Patients With Severe Aortic StenosisJACC: Cardiovascular Interventions, 2015
- Multicenter Evaluation of a Next-Generation Balloon-Expandable Transcatheter Aortic ValveJACC, 2014
- Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE StudyEuropean Heart Journal, 2014
- Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic StenosisNew England Journal of Medicine, 2012